Alector Inc (ALEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alector Inc (ALEC) has a cash flow conversion efficiency ratio of -1.360x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.69 Million) by net assets ($30.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALEC company net worth for the company's overall valuation and market capitalisation.
Alector Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Alector Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alector Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alector Inc ranked by their cash flow conversion efficiency. Explore Alector Inc (ALEC) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gamehost Inc.
TO:GH
|
0.046x |
|
Perma-Fix Environmental Svcs Inc
NASDAQ:PESI
|
-0.088x |
|
Froch Enterprise Co Ltd
TW:2030
|
-0.032x |
|
Seoyon E Hwa Co Ltd
KO:200880
|
0.100x |
|
technotrans SE
F:TTR1
|
-0.007x |
|
Digital Imaging Technology INC
KQ:110990
|
0.003x |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
0.174x |
|
CPE Technology Berhad
KLSE:5317
|
0.004x |
Annual Cash Flow Conversion Efficiency for Alector Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alector Inc from 2016 to 2025. View Alector Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.65 Million | $-184.03 Million | -6.004x | -231.17% |
| 2024-12-31 | $126.80 Million | $-229.91 Million | -1.813x | -32.08% |
| 2023-12-31 | $134.16 Million | $-184.16 Million | -1.373x | -1348.03% |
| 2022-12-31 | $214.44 Million | $-20.33 Million | -0.095x | -109.55% |
| 2021-12-31 | $300.72 Million | $298.55 Million | 0.993x | +259.29% |
| 2020-12-31 | $267.53 Million | $-166.73 Million | -0.623x | -22.22% |
| 2019-12-31 | $194.74 Million | $-99.31 Million | -0.510x | +61.03% |
| 2018-12-31 | $-97.40 Million | $127.46 Million | -1.309x | -483.18% |
| 2017-12-31 | $-52.03 Million | $-17.77 Million | 0.342x | -34.53% |
| 2016-12-31 | $-24.91 Million | $-12.99 Million | 0.522x | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more